At CD BioGlyco, we recognize the increasing global demand for natural, evidence-based solutions to manage hyperuricemia, a key precursor to gout and a factor in metabolic syndrome. Our uric acid-lowering seaweed oligosaccharide ingredient production service is a cutting-edge offering designed to meet this demand. It focuses on the customized, scalable production of high-purity seaweed oligosaccharides, which are gaining significant traction in the nutraceutical and functional food industries due to their proven bioactivity.
CD BioGlyco is specifically tailored to the functional food and nutraceutical market, focusing on the anti-hyperuricemic potential of seaweed oligosaccharides. The efficacy of these compounds often stems from their ability to inhibit key enzymes in the uric acid production pathway, such as xanthine oxidase, and/or to enhance uric acid excretion. Neoagarooligosaccharides (NAOs) derived from agar have exhibited significant xanthine oxidase inhibitory activity, thus reducing the production of uric acid. Mannuronate oligosaccharides (MOS) and guluronate oligosaccharides (GOS) derived from alginate effectively reduce serum uric acid levels, often by promoting uric acid excretion and exhibiting anti-inflammatory properties that mitigate symptoms associated with hyperuricemia.
Our primary service is providing clients with seaweed oligosaccharide raw materials that are customized to their specific application needs. This customization includes:
1. Source Biomass Selection and Pre-treatment
This initial stage involves careful selection of the most appropriate seaweed species (e.g., red, brown, or green algae) known for high yields of target polysaccharides. The biomass undergoes rigorous quality control, followed by optimized washing, drying, and grinding processes to prepare it for efficient extraction.
2. Target Polysaccharide Extraction
We employ advanced extraction methods, such as enzyme-assisted extraction (EAE) or optimized mild hot-water and acid/alkaline processes. This step isolates the high molecular weight precursor polysaccharides (e.g., agar, alginate, fucoidan) from the prepared seaweed biomass, maximizing yield while minimizing degradation of the complex polymer structure.
3. Controlled Depolymerization
The extracted polysaccharide is subjected to our core technologies—precision enzymatic or controlled chemical hydrolysis. The reaction conditions (enzyme concentration, pH, temperature, time) are precisely tuned based on the client's specifications for the desired DP and targeted bioactivity profile, leading to the generation of the functional oligosaccharides.
4. Fractionation and High-Purity Isolation
The resulting mixture of oligosaccharides and residual byproducts is processed through our advanced purification train. This step uses techniques like membrane separation and chromatography to remove impurities and isolate the target oligosaccharide fraction with the required purity and molecular weight range, which is critical for their biological activity.
5. Detailed Structural and Activity Validation
Before final formulation, the isolated oligosaccharide fraction undergoes comprehensive structural analysis using our advanced analytical tools to confirm molecular identity, purity, and DP distribution. Furthermore, its uric acid-lowering activity is validated via relevant in vitro assays, ensuring the ingredient meets the performance criteria.
6. Final Ingredient Formulation
The high-purity oligosaccharide product is dried (e.g., lyophilized or spray-dried) and formulated into the final ingredient format (powder, solution) according to client specifications. A final battery of quality assurance tests, including stability, microbial load, and heavy metal analysis, confirms the product's safety and quality, ready for commercial application.
DoI: 10.3390/md16120472
Journal: Mar Drugs
IF: 5.4
Published: 2018
Results: This study investigates the ameliorative effect and hepatorenal protective role of fucoidan from Laminaria japonica on adenine-induced hyperuricemic mice. Mice were administered different doses of fucoidan, allopurinol, or a vehicle control. Results showed fucoidan significantly reduced serum uric acid levels via dual regulation: inhibiting hepatic adenosine deaminase and xanthine oxidase activities to decrease urate production, and downregulating renal urate transporter 1 expression to promote urate excretion. Additionally, fucoidan reversed adenine-induced hepatorenal dysfunction, restored normal levels of antioxidant indicators, and suppressed NF-κB p65 activation to alleviate inflammatory damage. The findings demonstrate that fucoidan from Laminaria japonica is a potential therapeutic agent for hyperuricemia, possessing both uricostatic and uricosuric effects.
Fig.1 Fucoidan repressed adenine-induced expression and phosphorylation of NF-κB protein in the kidney of mice. (Zhang, et al., 2018)
Can you customize the DP for our specific application?
Absolutely. DP is a critical factor in both solubility and bioactivity. We will work with you to define the optimal DP range and engineer the production process to produce an ingredient tailored precisely to your formulation and target mechanism.
Are there any concerns regarding heavy metals or contaminants in the raw seaweed source?
We operate under strict quality control protocols, including screening raw biomass from certified suppliers and implementing purification steps that effectively eliminate heavy metals and environmental contaminants. Our final QA reports provide complete assurance of safety and compliance.
"CD BioGlyco's service was transformative for our new line of metabolic support supplements. The precision of their enzymatic hydrolysis delivered an neoagarooligosaccharide fraction with a molecular weight profile that perfectly matched our target bioactivity. Their analytical support was exceptional, providing the robust data we needed for substantiation."
- A.W., R&D Director
"We chose CD BioGlyco for their clear scientific expertise, and they exceeded our expectations. The team was highly responsive in customizing the alginate oligosaccharide raw material to meet the specific solubility demands of our functional products."
- H.B., Innovative Functional Products
"The transition from lab-scale to commercial-scale production of our specialized Fucoidan Oligosaccharide was seamless. CD BioGlyco's scalability, coupled with their rigorous QA/QC process, drastically reduced our risk."
- E.J., Global Health Ingredient Manufacturer
CD BioGlyco is your dedicated partner for the development and large-scale production of high-performance, uric acid-lowering seaweed oligosaccharide ingredients. Leveraging decades of specialized expertise and advanced enzymatic technology, we deliver customized, high-purity, and scientifically validated ingredients that offer a natural solution for hyperuricemia management. Please feel free to contact us to learn more about how our custom service can be integrated into your next market-leading product.
Reference